Seaport Therapeutics (Nasdaq: SPTX) is a clinical-stage biopharmaceutical company focused on developing novel oral medicines for neuropsychiatric disorders like depression and anxiety. Spun out of PureTech Health, the Boston-based company went public in May 2026, raising $254.9 million in an upsized initial public offering